Shares of Natera, Inc. (NASDAQ:NTRA) have been given an average rating of “Hold” by the eight research firms that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $15.75.

A number of equities research analysts have weighed in on NTRA shares. Zacks Investment Research lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Canaccord Genuity boosted their target price on shares of Natera from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, May 10th. ValuEngine lowered shares of Natera from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. BidaskClub lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Morgan Stanley decreased their target price on shares of Natera from $18.00 to $13.00 and set an “overweight” rating for the company in a research note on Monday.

Several large investors have recently bought and sold shares of NTRA. Russell Investments Group Ltd. bought a new stake in Natera during the fourth quarter valued at approximately $130,000. State Street Corp raised its stake in Natera by 2.9% in the fourth quarter. State Street Corp now owns 389,498 shares of the medical research company’s stock valued at $4,561,000 after buying an additional 11,067 shares during the period. Renaissance Technologies LLC raised its stake in Natera by 51.4% in the fourth quarter. Renaissance Technologies LLC now owns 320,800 shares of the medical research company’s stock valued at $3,757,000 after buying an additional 108,900 shares during the period. Teachers Advisors LLC raised its stake in Natera by 5.0% in the fourth quarter. Teachers Advisors LLC now owns 44,224 shares of the medical research company’s stock valued at $518,000 after buying an additional 2,116 shares during the period. Finally, Highbridge Capital Management LLC raised its stake in Natera by 119.7% in the fourth quarter. Highbridge Capital Management LLC now owns 41,686 shares of the medical research company’s stock valued at $488,000 after buying an additional 22,712 shares during the period. Hedge funds and other institutional investors own 59.74% of the company’s stock.

WARNING: “Natera, Inc. (NASDAQ:NTRA) Receives Average Recommendation of “Hold” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/natera-inc-nasdaqntra-receives-average-recommendation-of-hold-from-brokerages.html.

Natera (NASDAQ:NTRA) traded up 2.24% on Tuesday, hitting $8.20. The stock had a trading volume of 120,052 shares. The stock has a 50 day moving average price of $10.36 and a 200 day moving average price of $9.58. Natera has a 1-year low of $7.35 and a 1-year high of $13.08. The company’s market cap is $433.63 million.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, May 9th. The medical research company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.09. The company had revenue of $46.90 million for the quarter, compared to analysts’ expectations of $42.82 million. Natera had a negative net margin of 60.89% and a negative return on equity of 101.63%. Natera’s quarterly revenue was down 24.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. On average, equities research analysts expect that Natera will post ($1.98) EPS for the current fiscal year.

About Natera

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.